REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Clinical trials for REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to hold cancer at bay, paving way for potentially curative CAR-T
Disease control Recruiting nowThis study is testing a two-drug combination (golcadomide and rituximab) as a 'bridge' treatment for adults with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The goal is to control the cancer and improve patients' health so they can proceed to a…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New Two-Pronged attack tested for Tough-to-Treat lymphoma that returns
Disease control Recruiting nowThis study is testing a new treatment sequence for adults whose aggressive large B-cell lymphoma has come back or didn't respond to initial therapy. Participants first receive two targeted drugs (tafasitamab and lenalidomide), followed by a stronger chemotherapy regimen. The main…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG TYPE
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC